In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Selected Start-Ups (4/00)

Executive Summary

In Vivo summarizes the technologies of several recently founded companies: Ardais Corp., is creating information products from consolidating high-quality, reliable biological samples and related information for use in drug discovery and development. BeneCor Heart Systems was founded in September 1999 to develop and commercialize a totally implantable, permanent heart replacement device. Chronix Biomedical will focus on the diagnosis and management of chronic diseases by detecting what it calls "reshuffled genes," the detours the human genome map takes when confronted with viruses or other toxins. Founded in July 1999 by a group of former Columbia University physicians and scientists, MediData Solutions Inc. will offer new software and technology for managing clinical trials. Spiration is developing devices to treat pulmonary diseases, in particular chronic obstructive pulmonary disease (COPD), for which no cure exists.

You may also be interested in...



Stockwatch: Reading The Tea Leaves For Pharma Q1 Earnings

Contrasting first-quarter preannouncements from a DNA sequencing company and a molecular diagnostics company may, with other seasonal pressures, imply a comparatively weak first quarter for therapeutic drug companies.

EU Medtech May Have Standards Certainty Days Before MDR Applies

The EU’s Medical Device Regulation applies in just over a month’s time and the IVD Regulation in just over a year. But the standards underpinning them are way behind. Will they get the green light at last

Gilead Keeps Close Eye On Stormy Remdesivir Situation In India

Gilead is closely evaluating the situation for remdesivir in India as the country tackles shortages of the drug, which has several local licensees, with instances of black marketing adding to the local woes. The US firm clearly will not want any momentum towards possible compulsory licensing as initiated by Hungary and Russia, even as Indian firms have cut prices of the antiviral.

Related Companies

UsernamePublicRestriction

Register

IV001410

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel